AR055631A1 - Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada - Google Patents

Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada

Info

Publication number
AR055631A1
AR055631A1 ARP060103890A ARP060103890A AR055631A1 AR 055631 A1 AR055631 A1 AR 055631A1 AR P060103890 A ARP060103890 A AR P060103890A AR P060103890 A ARP060103890 A AR P060103890A AR 055631 A1 AR055631 A1 AR 055631A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
metformin
immediate release
prolonged
release
Prior art date
Application number
ARP060103890A
Other languages
English (en)
Inventor
Regalado Antonio Santiago
Leon Sixto Serafin Espinoza
Original Assignee
Silanes Sa De Cv Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38042925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silanes Sa De Cv Lab filed Critical Silanes Sa De Cv Lab
Publication of AR055631A1 publication Critical patent/AR055631A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion farmacéutica en forma de tabletas de estabilidad comprobada, así como su proceso de obtencion, en la cual se tienen dos principios activos consistentes en dos hipoglucemiantes orales: una sulfonilurea como la Glimepirida con liberacion inmediata en una fase y una biguanida como el clorhidrato de Metformina (Metformina HCl) con liberacion prolongada en otra fase, la tableta es para administracion oral preferentemente de una a dos veces al día, en una sola de estas tabletas bifásicas, es posible incluir más de 500mg de Metformina HCl, es decir hasta 1000 mg o 1500 mg, adaptándose segun los requerimientos diarios para cada paciente. La combinacion de estos hipoglucemiantes muestra un efecto sinérgico y por consiguiente una mayor efectividad en el control de los niveles de glucosa en sangre de personas con padecimiento de diabetes mellitus tipo 2. Reivindicacion 1: Una composicion farmacéutica estable en forma de tableta caracterizada por que comprende un nucleo o matriz que contiene una biguanida de liberacion prolongada; una capa o recubrimiento aislante de un polímero hidrofobico; y un recubrimiento que contiene una sulfonilurea de liberacion inmediata.
ARP060103890A 2005-09-08 2006-09-07 Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada AR055631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA05009633A MXPA05009633A (es) 2005-09-08 2005-09-08 Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.

Publications (1)

Publication Number Publication Date
AR055631A1 true AR055631A1 (es) 2007-08-29

Family

ID=38042925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103890A AR055631A1 (es) 2005-09-08 2006-09-07 Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada

Country Status (5)

Country Link
US (1) US20070264331A1 (es)
AR (1) AR055631A1 (es)
BR (1) BRPI0605026A (es)
CO (1) CO5900010A1 (es)
MX (1) MXPA05009633A (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061643A1 (es) * 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2
KR101536786B1 (ko) * 2007-07-19 2015-07-14 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20100330177A1 (en) * 2008-02-05 2010-12-30 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN101959406A (zh) * 2008-03-04 2011-01-26 默沙东公司 二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
EP2228066A1 (en) 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2438911A1 (en) 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
WO2012080833A2 (en) * 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
MX339374B (es) * 2011-04-29 2016-05-13 Inst De Investigación En Química Aplic S A De C V Cocristales ionicos con base en metformina.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072527A (en) * 1959-07-01 1963-01-08 Horner Frank W Ltd Use of tolbutamide in the treatment of acne
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
PT974356E (pt) * 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
MXPA03001157A (es) * 2000-08-07 2004-02-17 Ranbaxy Signature Llc Formulacion liquida de metformina.
WO2002055009A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003061643A1 (es) * 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
WO2004045622A1 (en) * 2002-11-15 2004-06-03 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs

Also Published As

Publication number Publication date
US20070264331A1 (en) 2007-11-15
BRPI0605026A (pt) 2007-04-17
CO5900010A1 (es) 2008-03-31
MXPA05009633A (es) 2007-03-07

Similar Documents

Publication Publication Date Title
AR055631A1 (es) Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
CL2008002052A1 (es) Compuestos derivados de pirazol, inhibidores de la 11 beta-hidroxi-esteroide-deshidrogenasa; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y uso para la preparacion de medicamentos para el tratamiento de diabetes, obesidad, trastornos de ingestion de comida o dislipidemia
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
ES2577930T3 (es) Derivados de triazina para retrasar el inicio de la diabetes tipo 1
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
RU2007116869A (ru) Комбинация органических соединений
DOP2013000085A (es) Formulacion de capsula
BRPI0516237A (pt) derivado de pirimidina fundido com anel não aromático
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
NO20074872L (no) Pyrazoler
PL1680128T3 (pl) Heksafosforan mio-inozytolu do stosowania miejscowego
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
ECSP077843A (es) Tratamiento o prevención del prurito
ATE361065T1 (de) Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
ATE361743T1 (de) Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
BRPI0613447A2 (pt) composição farmacêutica, usos de um agonista de ppargama e de um agente biguanida, e, kit para evitar ocorrência de efeitos colaterais adversos devido à ação de um agente biguanida no tratamento do diabetes
ECSP11010999A (es) Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina
BRPI0408805A (pt) composição farmacêutica contendo complexo de platina e método de fabricação da mesma
AR041856A1 (es) Tabletas de liberacion retardada de administracion por via oral y metodos de fabricacion y uso de las mismas
WO2006122069A3 (en) Formulations of mast cell stabilizing agents for delivery to the colon
ATE484288T1 (de) Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal